Press "Enter" to skip to content

New patent expiration for Abbvie Inc drug VIEKIRA XR

2
Copyright © DrugPatentWatch. Originally published at New patent expiration for Abbvie Inc drug VIEKIRA XR

Annual Drug Patent Expirations for VIEKIRA+XR
Annual Drug Patent Expirations for VIEKIRA+XR

Viekira Xr is a drug marketed by Abbvie Inc and is included in one NDA. There are twenty-one patents protecting this drug.

Drug patent litigation for VIEKIRA XR.

This drug has five hundred and twenty-seven patent family members in fifty-three countries.

The generic ingredient in VIEKIRA XR is dasabuvir sodium; ombitasvir; paritaprevir; ritonavir. Additional details are available on the dasabuvir sodium; ombitasvir; paritaprevir; ritonavir profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent expiration for Abbvie Inc drug VIEKIRA XR
Get the DrugPatentWatch Daily Briefing

✓ Patent Expirations and Generic Entry

✓ Insightful Articles & Case Studies

✓ Patent Litigation & Challenges

✓ 505(b)(2) & Biosimilars

✓ Industry Trends

Do NOT follow this link or you will be banned from the site!